The short answer
Each generation addressed the previous one's constraint. Exenatide showed a protease-resistant GLP-1 agonist was possible. Liraglutide added albumin binding. Semaglutide extended it to weekly. Tirzepatide and retatrutide then added receptors rather than duration.
Key facts
- Exenatide
- Gila monster venom; natural DPP-4 resistance
- Liraglutide
- C16 palmitic; daily
- Semaglutide
- Aib8 + C18 diacid; weekly
- Tirzepatide
- Added GIP
- Retatrutide
- Added glucagon
- Pattern
- Duration first, then receptors
The first problem was survival
Native GLP-1 has a half-life of one to two minutes because DPP-4 removes its first two residues. Exenatide solved this by accident of biology: it is exendin-4 from Gila monster venom, carrying glycine where human GLP-1 has alanine, which DPP-4 cannot process. The first workable GLP-1 agonist was found rather than designed.
Then the problem was duration
Protease resistance does not prevent renal filtration. Liraglutide attached a C16 palmitic acid to bind albumin, reaching about 13 hours, enough for daily dosing. Semaglutide combined a stronger C18 diacid with an Aib substitution blocking DPP-4 directly, reaching roughly a week. Two generations of the same idea at increasing intensity.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Then the constraint changed
Once weekly dosing was achieved, extending duration further stopped being the bottleneck. Effect size became the limit, and the field turned from pharmacokinetics to pharmacology, adding receptors rather than adding hours. Tirzepatide added GIP; retatrutide added glucagon.
What retatrutide inherits
All of it. The albumin-binding lipid is liraglutide's idea at semaglutide's intensity. The protease-resistant design descends from exendin-4's accidental glycine. The GIP scaffold is tirzepatide's. Retatrutide is not a departure from the first-generation compounds so much as the accumulation of every solution they produced.
What stayed constant
Gastrointestinal adverse effects, at every generation and every receptor combination. They follow from GLP-1 receptor pharmacology itself (delayed gastric emptying and area postrema signalling) rather than from any design decision, which is why thirty years of engineering has not removed them.
And what changed direction
Orforglipron and aleniglipron abandon the peptide entirely, trading effect size for oral administration. That is the first real branch in the lineage rather than another step along it, and it is why 2026 looks like the year the field split rather than advanced.
Frequently asked questions
What was the first GLP-1 agonist?
Exenatide, a synthetic form of exendin-4 from Gila monster venom, which resists DPP-4 naturally because it carries glycine where human GLP-1 has alanine.
Why did the field stop extending half-life?
Once weekly dosing was achieved, duration stopped being the constraint. Effect size became the limit, so development turned to adding receptors.
Do the newer compounds have fewer side effects?
No. Gastrointestinal effects follow from GLP-1 receptor pharmacology itself and have persisted across every generation.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedCoskun T et al. Cell Metab 2022 (PMID 35985340)pubmed.ncbi.nlm.nih.gov
- PubMedExendin-4 from Heloderma suspectum venom. Basic Clin Pharmacol Toxicol 2019 (PMID 30417596)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · Liraglutide (CID 16134956)pubchem.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066). Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05929079). Retatrutide in type 2 diabetesclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05882045). Retatrutide + established CVDclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-4 (NCT05931367). Retatrutide once weeklyclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-5 (NCT06662383). Retatrutide vs tirzepatideclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268). Maintenance of weight reductionclinicaltrials.gov
- PubMedJastreboff AM et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023 (PMID 37366315)pubmed.ncbi.nlm.nih.gov
- PubMedRosenstock J et al., Retatrutide for people with type 2 diabetes. Lancet 2023 (PMID 37385280)pubmed.ncbi.nlm.nih.gov
- DrugBankDrugBank · Retatrutide (DB18435)go.drugbank.com
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More Retatrutide Research articles
- Retatrutide Storage and StabilityA lipidated 39-mer is more surface-active than most peptides. Why foaming matters more here, and what the fatty acid changes about handling.
- Retatrutide Molecular Weight4,731.33 Da is the figure everyone quotes. It comes from supplier sources rather than a primary database, and at least one reference gives a different formula.
- Retatrutide in the Published LiteratureA small literature of unusually high quality - Cell Metabolism, NEJM, the Lancet - and a Phase 3 programme of more than 5,800 participants.
- What Is the TRIUMPH Trial Programme?TRIUMPH is Eli Lilly's Phase 3 programme for retatrutide: 5,800+ participants. TRIUMPH-1 reported 28.3% mean weight reduction at 80 weeks in May 2026.
- How One Peptide Engages Three ReceptorsGIPR, GLP-1R and GCGR belong to one receptor family, which is what makes a single-molecule triple agonist possible at all.